The Hong Kong Patent Office granted HK Patent No. HK40097814 to Envoy Medical Corporation on January 3, 2025. The title is Programming of Cochlear Implant Accessories. This patent relates to a system ...

Shareholder distributions are appropriate. Capital intensity of the industry remains low and gross margins high. In addition, Cochlear enjoys high cash conversion, enabling it to typically pay out 70% ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

Tax reform needs to be firmly on the agenda ahead of the looming federal election, Cochlear chief executive Dig Howitt says, ...

The S&P/ASX 200 hit an all time high on February 14, 2025 but AMP and Cochlear fell heavily on results, ... Read More The ...

Cochlear (ASX: COH) shares are trading at the lowest level since December 2023 after the company reported a ...

Cochlear shares were on track for their worst session in five years on Friday, after the Australian hearing implants maker reported first-half profit below estimates and forecast annual earnings at ...

Cochlear (ASX:COH) will pay an 8% higher dividend, with profits up 7% for the half year to the end of 2024 despite falling ...

The Cochlear Ltd (ASX: COH) share price is sinking on Friday after the hearing solutions company's half year result ...

Cochlear Limited (ASX: COH) has reported a 5 percent increase in revenue to $1,170 million for the first half of the 2025 ...

Cochlear expects full-year earnings to come in at the lower end of guidance, despite rising sales of its implants.